Pharming Group N.V.
PHAR
$10.00
$0.29193.01%
NASDAQ
| 12/31/2024 | 06/30/2024 | 12/31/2023 | 09/30/2023 | ||
|---|---|---|---|---|---|
| Revenue | 14.10% | 34.97% | 48.69% | 22.99% | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | 14.10% | 34.97% | 48.69% | 22.99% | |
| Cost of Revenue | 71.58% | 39.43% | 13.45% | 260.65% | |
| Gross Profit | 8.58% | 34.45% | 53.26% | 12.46% | |
| SG&A Expenses | -18.71% | 8.15% | 35.80% | 11.14% | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -100.69% | -7.55% | 55.70% | 49.33% | |
| Total Operating Expenses | -16.13% | 9.25% | 32.82% | 39.55% | |
| Operating Income | 176.70% | 80.22% | 15.24% | -75.54% | |
| Income Before Tax | 428.80% | -101.77% | 88.77% | -64.44% | |
| Income Tax Expenses | 249.73% | -43.98% | 131.63% | -178.50% | |
| Earnings from Continuing Operations | 191.55% | -192.34% | 78.65% | -61.93% | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | 191.55% | -192.34% | 78.65% | -61.93% | |
| EBIT | 176.70% | 80.22% | 15.24% | -75.54% | |
| EBITDA | 351.07% | 91.88% | 30.10% | -55.82% | |
| EPS Basic | 184.78% | -190.00% | 80.51% | -64.29% | |
| Normalized Basic EPS | 135.19% | 99.39% | 35.20% | -- | |
| EPS Diluted | 176.09% | -220.00% | 80.51% | -61.54% | |
| Normalized Diluted EPS | 135.19% | 99.39% | 35.20% | -- | |
| Average Basic Shares Outstanding | 9.63% | 2.52% | 8.87% | 6.58% | |
| Average Diluted Shares Outstanding | 9.63% | 2.52% | 8.87% | -1.03% | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |